Literature DB >> 19707844

Future drugs for migraine.

Luigi Alberto Pini1.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19707844     DOI： 10.1007/s11739-009-0299-3

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  13 in total

1.  European principles of management of common headache disorders in primary care.

Authors:  T J Steiner; K Paemeleire; R Jensen; D Valade; L Savi; M J A Lainez; H-C Diener; P Martelletti; E G M Couturier
Journal:  J Headache Pain       Date:  2007-10       Impact factor: 7.277

2.  Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.

Authors:  Brianne Weiss; Andrew Alt; Ann Marie Ogden; Mary Gates; Donna K Dieckman; Amy Clemens-Smith; Ken H Ho; Keith Jarvie; Geihan Rizkalla; Rebecca A Wright; David O Calligaro; Darryle Schoepp; Edward L Mattiuz; Robert E Stratford; Bryan Johnson; Craig Salhoff; Mary Katofiasc; Lee A Phebus; Kathryn Schenck; Marlene Cohen; Sandra A Filla; Paul L Ornstein; Kirk W Johnson; David Bleakman
Journal:  J Pharmacol Exp Ther       Date:  2006-05-11       Impact factor: 4.030

3.  Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal period.

Authors:  Ravi Gupta; Tanzeel Ahmed; Basudeb Banerjee; Manjeet Bhatia
Journal:  J Headache Pain       Date:  2009-03-11       Impact factor: 7.277

4.  Evidence of persistent central sensitization in chronic headaches: a multi-method study.

Authors:  Elena Filatova; Nina Latysheva; Alexey Kurenkov
Journal:  J Headache Pain       Date:  2008-08-09       Impact factor: 7.277

5.  The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.

Authors:  Boris A Chizh; Mary B O'Donnell; Antonella Napolitano; Jie Wang; Allison C Brooke; Mike C Aylott; Jonathan N Bullman; Emily J Gray; Robert Y Lai; Pauline M Williams; Jonathan M Appleby
Journal:  Pain       Date:  2007-07-30       Impact factor: 6.961

6.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321

7.  BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache.

Authors:  K A Maubach; R J Davis; D E Clark; G Fenton; P M Lockey; K L Clark; A W Oxford; R M Hagan; C Routledge; R A Coleman
Journal:  Br J Pharmacol       Date:  2009-01-19       Impact factor: 8.739

Review 8.  Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review.

Authors:  Peer Tfelt-Hansen; Han Le
Journal:  J Headache Pain       Date:  2009-03-28       Impact factor: 7.277

9.  Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.

Authors:  Erling Tronvik; Lars J Stovner; Grethe Helde; Trond Sand; Gunnar Bovim
Journal:  JAMA       Date:  2003-01-01       Impact factor: 56.272

Review 10.  From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries.

Authors:  Marta Allena; Zaza Katsarava; Giuseppe Nappi
Journal:  J Headache Pain       Date:  2009-02-24       Impact factor: 7.277
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.